Spinout Active LTD

Company profile

Phenotypeca Limited

Phenotypeca

Phenotypeca Limited is a UK company with status active founded in 2018 based in East Midlands.

CRN
11700555
Founded
2018
Age
7

Overview

Browse spinouts
Legal name
PHENOTYPECA LIMITED
Region
East Midlands
Registered address
CAWLEY HOUSE
149-155 CANAL STREET
NOTTINGHAM
NOTTINGHAMSHIRE
UNITED KINGDOM
NG1 7HR
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Phenotypeca Limited
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

6 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

10 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

26 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

21 Feb
2025

Capital Allotment Shares

Capital

SH01 | Transaction MzQ1NjAwNjI1M2FkaXF6a2N4

Published 21 Feb 2025 05:06

28 Nov
2018

Incorporated

Inception

Company registered at Companies House

Spinout profile

4 entries

Company description

Phenotypeca produces bakers yeast strains for the use in biotechnology processes.

Phenotypeca provides novel biologics production strains of the regulatory friendly baker's yeast, Saccharomyces cerevisiae for the manufacture of biologicals. We offer world leading yeast technology to rapidly provide cost-effective production strains optimised for specific biotechnology processes. This is achieved by harnessing the natural diversity in up to a billion different yeast cells to identify those with the ideal phenotypes and performance characteristics for industrial process conditions. Working with our customers we aim to improve access to life-saving medicines and promote sustainable manufacturing. With baker's yeast now fully established for the safe and economic production of FDA approved biologics, such as insulins and vaccines, our technology is ideal for taking bioprocesses to the next level.

Project impact

As a recent startup there is limited impact at the moment. There are 6 salaried employees, one full time research scientist, a scientific officer, a research director, business director and tech support. An Innovate UK award for proof of principle was awarded in January 2020 which subcontracts some work to the University lab in Leicester.

Phenotypeca
2018
Phenotypeca
2018
Phenotypeca
2018
Phenotypeca Ltd
2018

Public funding

3 awards
First funded
2020
Funded years
2020, 2021
Age at first award
1 years

Projects

2021 Feasibility Studies Lead participant

PhenoDev: A novel Saccharomyces cerevisiae platform for high-yield protein secretion

1 Oct 2021 to 31 Jan 2023

Awarded
£197,326
Total cost £281,894

Recombinant therapeutic proteins and many vaccines are costly to manufacture. Current state-of-the-art protein expression systems include: * Mammalian Chinese Hamster Ovary (CHO) and HEK293 systems. _Limitations:_ Slow-growing cells, expensive media, high energy burden (e.g., for supplying CO2, and for heating the cell cultures), high environmental burden...

2020 Feasibility Studies Lead participant

The development of yeast strains to produce SARS-CoV-2 antigens for serological assays enabling the detection of COVID-19 cases in the UK population

1 Jun 2020 to 31 Mar 2021

Awarded
£73,357
Total cost £73,357

Phenotypeca Ltd is a biotechnology company based in the University of Nottingham's Synthetic Biology Research Centre developing next-generation yeast for the manufacture of recombinant proteins, such as biopharmaceuticals. Using a genetically diverse collection of natural baker's yeast engineered for large-scale industrial processes we breed up to a billi...

2020 Study Lead participant

Development of second-generation S. cerevisiae hosts for enhanced protein yield and quality

1 Jan 2020 to 30 Sep 2021

Awarded
£155,495
Total cost £222,136

Recombinant protein expression is the keystone manufacturing technique supporting production of many biological therapies. A large number of protein expression systems exist, but the majority of biological drugs and protein products that are approved for clinical use have been manufactured using mammalian cell culture techniques. These manufacturing proce...

Product types

Feasibility Studies Study